Bmo, Czech Republic; Faculty Hospital Brno
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Hradec Kralove, Czech Republic; Faculty Hospital Hradec Kralove
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Novy Jicin, Czech Republic; Onkologicke centrum J.G. Mendela
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Prague, Czech Republic; Faculty Hospital Kralovske Vinohrady
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Prague, Czech Republic; General Faculty Hospital,
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Bayonne, France; Centre Hospitalier de la côte basque/Bayonne
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Brest, France; CHU BREST
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Caen, France; CHU Clémenceau
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Creteil, France; CHU Creteil
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Grenoble, France; CHU Michallon
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Limoges, France; CHU de Limoges
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Marseille, France; Institut Paouli Calmette
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Montpellier, France; CHU Montpellier/Lapeyronie
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Nantes, France; CHU Nantes
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Nice, France; CHU NICE
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Paris, France; CIC St Louis
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Pessac, France; CHU Bordeaux
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Pierre-Benite Cedex, France; Centre Hospitalier Lyon Sud
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Poitiers, France; Hopital Jean Bernard
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Reims, France; Hopital Robert Debre
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Rennes, France; Centre Hospitalier et Universitaire
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Vandoeuvre-les-Nancy, France; Hopital d'adultes de Brabois
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Villejuif, France; Institut Gustave Roussy
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Essen, Germany; Uniklinik Essen
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Hamburg, Germany; Allgemeines Krankenhaus St. Georg
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Homburg/Saar, Germany; Universitätskliniken des Saarlande
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Kiel, Germany; Universitätsklinikum Schleswig-Holstein
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Mönchengladback-Rheydt, Germany; Practice for Hematology and Oncology, At the Elisabeth-Krankenhaus Rheydt
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Reims, Germany; Justus-Liebig-Universität
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Ulm, Germany; Universitätsklinikum Ulm
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Budapest, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Debrecen, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Gyor, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Gyula, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Kaposvar, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Miskolc, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Nyiregyhaza, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Pecs, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Szeged, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Szekesfehervar, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Szekszard, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Szolnok, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Szombathely, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Tatabanya, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Veszprem, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Zalaegerszeg, Hungary; Research Site:
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Bari, Italy; Università degli studi di Bari- Ospedale Policlinico
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Bologna, Italy; Università degli studi di Bologna
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Milano, Italy; Ospedale Niguarda Cà Granda
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Rozzano (MI), Italy; Istituto Clinico Humanitas
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Nijmegen, Netherlands; University Medical Centre Nijmegen
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Amersfoort, Netherlands; Meander Medical Center
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Amsterdam, Netherlands; University of Amsterdam
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Enschede, Netherlands; Medisch Spectrum Twente
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Groningen, Netherlands; University Medical Center Groningen
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Gdansk, Poland; Klinika Hematologii AM
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Krakow, Poland; Klinika Hematologii CMUJ
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Lodz, Poland; Regionalne Centrum Onkologii
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Lodz, Poland; Klinika Hematologii AM
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Lublin, Poland; Centrum Onkologii Ziemi Lubelskiej
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Olszytyn, Poland; Regionalne Centrum Onkologii w Olszytynie Oddzial Chemioterapii
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Poznan, Poland; Klinika Hematologii CMUJ
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Siedlce, Poland; Wojewodzki Szpital Specjalistyczny
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Warszawa, Poland; Instytut Hematologii i Transfuzjologii
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Warszawa, Poland; Onkologii i Chorob Wewnetrznych AM
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Warszawa, Poland; Klinika Nowotworow Ukladu Chlonnego
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Wrocalw, Poland; Klinika Hematologii AM
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Badalona, Spain; Hospital Germans Trias i Pujol
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Barcelona, Spain; Hospital del Mar
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Barcelona, Spain; Hospital de la Santa
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Cadiz, Spain; Hospital Universitario Puerta del Mar
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Llobregat, Spain; L´Hospitalet del Llobregat
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Madrid, Spain; MD ANDERSON International
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Valencia, Spain; Hospital Universitario La Fe
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Lund, Sweden; University Hospital in Lund
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Lund, Sweden; University Hospital in Lund
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Sundsvall, Sweden; Sundsvall Hospital
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Aberdeen, United Kingdom; Aberdeen Royal Infirmary
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Belfast, United Kingdom; Belfast City Hospital
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Cardiff, United Kingdom; Velindre Hospital
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Liverpool, United Kingdom; Royal Liverpool University Hospital, Department of Haematology
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
London, United Kingdom; University College Hospital
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
London, United Kingdom; St. George's Healthcare NHS Trust
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Manchester, United Kingdom; Christie Hospital NHS Trust
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Northwood, Middlesex, United Kingdom; Mount Vernon Hospital
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Plymouth, United Kingdom; Derriford Hospital, Department of Haematology
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Southampton, United Kingdom; Southampton General Hospital
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
Worcester, United Kingdom; Worcestershire Royal Hospital
If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.
